Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the end of April, 2020, over 3 million people had been confirmed infected, with over 1 million in the USA alone, and over 215 000 dea...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Peter M, Wells, Athol U, Jenkins, R Gisli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Personal View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228727/
https://www.ncbi.nlm.nih.gov/pubmed/32422178
http://dx.doi.org/10.1016/S2213-2600(20)30225-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228727/
https://www.ncbi.nlm.nih.gov/pubmed/32422178
http://dx.doi.org/10.1016/S2213-2600(20)30225-3

Ejemplares similares